NCT03035357 2024-05-03
Neoadjuvant Listeria or Daratumumab in Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Withdrawn
Clinical Trials
7 trialsNCT04223661 2022-12-08
Frailty Score-guided Dosing of Lenalidomide, Dexamethasone and Daratumumab Induction Therapy
Indiana University
Phase 2 Withdrawn
NCT03841565 2022-06-15
Daratumumab, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma
Academic and Community Cancer Research United
Phase 2 Withdrawn
NCT04230031 2022-04-21
Phase II Study of Daratumumab Pre-Mobilization and Post-ASCT in Multiple Myeloma
Wake Forest University Health Sciences
Phase 2 Withdrawn
NCT04024384 2020-03-27
DARALLO
Assistance Publique - Hôpitaux de Paris
Phase 2 Withdrawn
NCT03221634 2019-03-25
Efficacy and Safety Study of Pembrolizumab (MK-3475) in Combination With Daratumumab in Participants With Relapsed Refractory Multiple Myeloma (MK-3475-668/KEYNOTE-668)
Merck Sharp & Dohme LLC
Phase 2 Withdrawn
NCT03207542 2018-07-26
Trial Evaluating the Efficacy and Safety of Daratumumab in Subjects With Relapsed/Refractory B-cell or T-cell Precursor Acute Lymphoblastic Leukemia (ALL)
M.D. Anderson Cancer Center
Phase 2 Withdrawn